Copyright Spencer Platt, Getty Images
Pfizer

Pfizer Won't Pursue Splitting in Two Separate Companies

Sept. 26, 2016
Investors have been waiting for a decision since 2012, when Goldman Sachs Group Inc. analysts suggested the company was heading down the path to separation.

Pfizer Inc. decided not to pursue a strategy of breaking into two separate companies after an “extensive evaluation.”

The board and an executive team decided the U.S. drugmaker is “best positioned to maximize future shareholder value creation in its current structure and will not pursue splitting Pfizer Innovative Health and Pfizer Essential Health into two, separate publicly traded companies at this time,” Pfizer (IW 500/22) said in a statement on Monday.

Investors have been waiting for a decision since 2012, when Goldman Sachs Group Inc. analysts suggested the company was heading down that path. Pfizer has separated some operations internally, and breaks out separate financial results for what it calls its Innovative Health and Essential Health units.

The decision doesn’t affect the financial guidance for 2016, which Pfizer reaffirmed. Both units have delivered solid year-over-year performance over the course of the past three years, demonstrating their ability to compete on a standalone basis, Pfizer said.

By Marthe Fourcade

About the Author

Bloomberg

Licensed content from Bloomberg, copyright 2016.

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!